| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K70511574 | CTRPv2 | pan-cancer | AAC | -0.047 | 0.2 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.047 | 0.2 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.074 | 0.2 |
| mRNA | 17-AAG | FIMM | pan-cancer | AAC | 0.31 | 0.2 |
| mRNA | KU-55933 | CTRPv2 | pan-cancer | AAC | -0.052 | 0.2 |
| mRNA | KH-CB19 | CTRPv2 | pan-cancer | AAC | -0.066 | 0.2 |
| mRNA | PHA-665752 | CCLE | pan-cancer | AAC | -0.071 | 0.2 |
| mRNA | Bax channel blocker | CTRPv2 | pan-cancer | AAC | -0.055 | 0.2 |
| mRNA | TAE684 | GDSC1000 | pan-cancer | AAC | -0.074 | 0.2 |
| mRNA | etomoxir | CTRPv2 | pan-cancer | AAC | -0.054 | 0.2 |